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ABSTRACT Currently, little is known about the molecular recognition pathways between DNA-alkylating anticancer drugs and
their targets despite their pharmacological relevance. In the framework of classical molecular dynamics simulations, here we
use umbrella sampling to map the potential of mean force (PMF) associated with sliding along the DNA minor groove of two of
these compounds. These are an indole derivative of duocarmycin (DSI) and the putative reactive form of anthramycin (anhydro-
anthramycin, IMI). Twenty-three conﬁgurations were considered for each drug/DNA complex, corresponding to a movement
along ;3 basepairs. The alkylation site turns out to be the most favorable for DSI, while a barrier of ;6 kcal/mol separates the
reactive conﬁguration of IMIDNA from the absolute minimum. An analysis of various contributions to the PMF reveals that
solvent effects play an important role for the largest and more ﬂexible drug DSI. Instead, the PMF of IMIDNA overall correlates
with changes in the binding enthalpy. Implications of these results on the sequence selectivity of the two drugs are discussed.
INTRODUCTION
Most of the successful anticancer drugs targeting DNA are
organic molecules which form noncovalent or covalent in-
teractions in the minor groove with different sequence se-
lectivity (1,2). To rationally design such drugs, both the
structure and the microscopic mechanisms underlying drug-
target interactions should be known. Furthermore, it is very
important to design sequence-selective anticancer molecules
(hopefully competitive with regulatory proteins) that bind to
regions of DNA involved in replication and transcription
processes (3–6).
In this respect, a number of noncovalent binders were well
characterized, and sequence-speciﬁc readout codes were
partly deciphered (1,7). In contrast, the important class of
DNA-alkylating agents has received less attention, particu-
larly from a theoretical point of view, partly because of the
paucity of experimentally determined structural data (8).
Binding of these drugs is believed to occur in two steps (9):
the formation of the noncovalent adduct D1T/Kb D  T;
followed by the covalent linkage of the drug to the DNA
D  T/kr D T: The design of new covalent binders re-
quires identiﬁcation and characterization of the transition
state associated with the rate-determining step, since its
subtle tuning affects rate and routes of interactions. Both
these factors inﬂuence the reactivity and consequently the
efﬁcacy of the drug (10).
It is commonly accepted that molecular recognition and
formation of the noncovalent complex are driven by non-
speciﬁc interactions and sequence-speciﬁc structural features
along the minor groove (8). Recently, molecular dynamics
(MD) studies by us (11,12) have provided information at the
molecular level on the noncovalent interaction between the
DNA and two covalent binders, anthramycin (13–16) and
duocarmycin (17,18). Anthramycin alkylates guanines, show-
ing a modest sequence selectivity for PuG*Pu sequences
(16), whereas duocarmycin binds to adenines and is very
selective toward AT-rich sequences which have to be at least
4 basepairs (bp) long (17,18). Both anthramycin and duocar-
mycin are powerful cytotoxic agents interfering with transcrip-
tion and replication processes, and some of their derivatives
have entered clinical test phases (19,20). The natural twist of
35 between phenol and pyrrol rings (respectively A and C in
Chart 1) gives to anthramycin the ideal shape to ﬁt into the
minor groove (14). In contrast, the largest duocarmycin is
formed by two moieties connected via an amide link (Chart
1), and to ﬁt into the minor groove it needs a 40 twist around
the amide link relative to its conformation in water (18).
For the purposes of this work, we focus on the putative
reactive imine form of anthramycin (hereafter IMI, Chart 1)
(13–16) and on duocarmycin-SI (hereafter DSI, Chart 1)
(17,18). Noncovalent complexes of both IMI and DSI with
DNA are mainly stabilized through hydrophobic interactions
(11,12). However, although IMI forms a relatively strong
H-bond network with DNA (12,14), only one H-bond is
formed between DSI and DNA (11,18). In a previous MD
simulation performed in our group (12), IMI turned out to
slide along the minor groove of a d[GCCAACGTTGGC]2
duplex, leading to the formation of a nonreactive stable
complex. Such a sliding is independent on the initial location
of the drug, occurring when IMI sits either at the end or in the
middle of a DNA duplex. The same kind of displacement has
been observed after docking the molecule to its preferred
site, the triplet AGA (16), within a 14-mer duplex (data not
shown). Instead, the complex between DSI and the duplex
d[GACTAATTGAC]2 is stable during the whole dynamics
(11). It is worthwhile to notice that a similar shufﬂing
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mechanism was suggested by footprinting experiments for a
photoactive derivative of actinomycin, while noncovalent
translocation mechanism has been invoked for the covalent
binder CC-1065 (21,22).
As the noncovalent recognition of the preferred DNA
sequence may involve a sliding of drugs along the minor
groove, knowledge of the energetics of such processes may
provide useful information on ligand selectivity and molec-
ular recognition. Here we address this issue by investigating
quantitatively the mechanism of sliding of IMI and DSI.
Because of the increasing reliability ofmethods for simulating
DNA (23–28), nowadays it has become possible to extract
free energies of drug/DNA recognition fromMD simulations
(29,30). The free energy is then dissected at a qualitative level
into its enthalpic and entropic contributions, the rank ofwhich
has been shown to depend strongly on the chemical structure
of the drug and on the DNA sequence (31,32).
We ﬁnd that for IMI, binding to the reactive site is less
favored than at nearby bp, whereas for DSI the noncovalent
binding site coincides with the reactive one, in agreement with
previous MD simulations (11,12). Although the potential of
mean force (PMF) associated to the sliding of IMI can be
roughly rationalized through a simple analysis of drug/DNA
enthalpic interactions, solvation effects appear to be much
more relevant for DSI as a consequence of more stringent re-
quirements for optimal ﬁt of drug into the minor groove. Our
ﬁndings suggest the need to consider multiple binding path-
ways in drug design and provide a rationale for the modest
selectivity of anthramycin relative to duocarmycin (18,33).
SYSTEMS AND METHODS
Free energy proﬁles were calculated as a function of the position of the
drug along the minor groove for the noncovalent complexes of IMI with
d(GCCAACGTTG*GC)-d(GCCAACGTTGGC) (hereafter IMIDNA) and
DSI with d(GACTAATTGAC)-d(GTCAATTA*GTC) (hereafterDSIDNA).
These are built starting from experimental structures (14,18) by cutting the
covalent bond between the carbon of the drug and the nitrogen of the
nucleobase and manually pulling out the drugs from the minor groove until
the distance d[C-N] was ;3.3 A˚. As DSI moves toward the nearest end of
the duplex upon sliding, test calculations were performed to investigate the
possible inﬂuence of end effects (12). To this end, we constructed an addi-
tional 14-mer d(GACGACTAATTGAC)-d(GTCAATTA*GTCGTC) (here-
after DSIDNAc), and DSI was placed with its reactive carbon C13 in front
of the base T24 (corresponding to T21 in DSIDNA). A 7 ns MD simulation
was performed on this system, and analyses were performed on the last 2 ns.
All simulations were carried out using the GROMACS package (34–36).
AMBER/gaff force ﬁelds (25,26,37,38) were used for the parameterization of
oligonucleotides and drugs (see Spiegel et al. (11) and Vargiu et al. (12) and
Supplementary Material Tables S1 and S2). Drug structures were optimized
by means of DFT calculations at the B3LYP/6-31G(d,p) (39,40) level, using
theGaussian03 package (41). Atomic restrained electrostatic potential (RESP)
charges (42) were derived using the resp module of AMBER after wave
function relaxation. Potassium ions, modeled with the AMBER-adapted
Aqvist potential (43), were added to achieve charge neutrality (22, 20, and 28
in IMIDNA and DSIDNA and DSIDNAc, respectively). Systems were
solvated with a cubic box of TIP3P water molecules (44), ensuring that the
solvent shell would extend for at least 12 A˚ around the DNA. Periodic bound-
ary conditions were used, and constant temperature-pressure (T ¼ 300 K,
P ¼ 1 atm) dynamics were performed through the Nose´-Hoover (45,46) and
Andersen-Parrinello-Rahman (47,48) coupling schemes (t ¼ 1 ps). Elec-
trostatic interactions were treated using the particle mesh Ewald algorithm
(49) with a real space cutoff of 10 A˚, the same as for van der Waals in-
teractions. The pair list was updated every 10 steps, and Lincs constraints
(50) were applied to all bonds involving hydrogen atoms, allowing us to use a
time step of 2 fs. Coordinates were saved each 500 steps, corresponding to
1,000 snapshots per ns. The DNA minor groove width was deﬁned as the
distance between sugar C49 atoms, and it was calculated with the program
Curves (51–53).
The PMFs (54) associated to drug sliding along the minor groove of
IMIDNA and DSIDNA were calculated with the umbrella sampling
method (55). The distance between the reactive atoms of drug and DNA base
(speciﬁcally the C11 atom of IMI to the N2 atom of guanine 10 in the DNA
and atom C13 of DSI to atom N3 in adenine 19 of the DNA) was chosen as
the reaction coordinate. This simple choice is well suited to describe move-
ments of the drugs that are a few bps long, since both compounds cause no
appreciable bending of DNA (11,12). To sample the various conformations
corresponding to different positions of the drug along the minor groove, we
imposed a harmonic constraint of 15 kcal/(molA˚2) to the distance d[C-N]
from 2.9 A˚ to 12.1 A˚ with a step of 0.4 A˚. Doing so the total movement of
9.2 A˚ (slightly less than 3 bps steps) is partitioned into 23 windows (see
movies in the Supplementary Material). Initial conﬁgurations of each win-
dow were generated starting from the reactive one and increasing the dis-
tance d[C-N] by steps of 0.2 A˚, after 70 ps of equilibration for each d[C-N]
value. The weighted histogram analysis method (56) was used to recombine
PMF obtained from different windows. As can be seen from insets in Figs.
1 and 2, the error on the calculated PMFs is almost constant, meaning that
the reaction coordinate was sampled in a fairly uniform manner.
Extended MD simulations of oligonucleotides in water (57) indicate that
some of the DNA conformational and helicoidal parameters have relaxation
times of ;0.5 ns. Thus, at least multi-ns trajectories must be collected to
obtain well-converged free energy proﬁles (58,59). Systems investigated
CHART 1 Schematic view of alkylation of guanine by IMI (left) and adenine by DSI (right).
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here needed almost 4 ns of equilibration phase, although the PMF landscape
roughly converged after 2 ns (see Supplementary Material Fig. S1 for the
proﬁle ofDSIDNA; similar results are found for IMIDNA). A further check
on the RMSD of drugDNA complexes indicates that convergence was
reached for all of the windows after;4 ns (Supplementary Material Fig. 2S,
A and B). Thus, we performed 6 ns of MD simulation on each window (for a
total of ;140 ns), and we used the last 2 ns for extracting the PMF and for
the structural analysis of the complexes.
The PMF was decomposed as the sum of individual components, each
with a physical meaning and evaluated via the force ﬁeld terms. In particular,
we examined variations in the drug-DNA electrostatic and van der Waals
interactions, solute adaptation energy, solute conﬁgurational entropies, and
solvation free energies. Energetic contributions were evaluated as MD aver-
ages, using terms in the force ﬁeld (25,26,38). Van der Waals interactions
were roughly estimated by summing the number of hydrophobic contacts for
each atom-type pair. For each of these, the equilibrium distance d0 of the
Lennard-Jones potential was estimated (Supplementary Material Table S3, A
and B), and we considered a contact if d , (d0 1 0.2 A˚). Solute vibrational
entropies were calculated within the harmonic approximation (60), using the
nmodemodule ofAMBER9 (61).As customary (62–64),we selected a subset
of structures for this analysis (20 for each relevant conﬁguration, extracted
every 0.1 ns from the last 2 ns). These were minimized in the absence of
solvent, using instead a dielectric constant e¼ 4r (r is the interatomic distance
in A˚) to mimic solvent effects. Then, up to 20,000 steps of minimization with
no cutoff for all the interactions were performed, of which the ﬁrst 100 are
steepest descent followed by conjugate gradient, until the RMS of gradient
FIGURE 1 (a) PMF associated to IMI sliding along the DNAminor groove. Standard deviation is reported in the inset. (b) Schematic view of the complex in
the conﬁguration corresponding to the free energy minimum. (c) Structures of three relevant conformations of the drug/DNA complex. The second and third
structures (from the left) were rotated respectively by;30 and;100 about the helical axis to center the drug for visualization. Molecular surfaces of drug and
DNA are depicted in transparent red and blue, respectively. Figures created with the program VMD (76).
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drops below 104 kcal/(molA˚). The estimate of relative solute conforma-
tional entropies is not a trivial task (63,65), in particular for very ﬂexible
systems such as oligonucleotides.Moreover, it is not possible to guess a priori
how the ‘‘spreading’’ of the dynamics among the various basins of the free
energy surface depends on the conformation (i.e., the position of the drug).
Note that also using the quasiharmonic model relative entropies are sensitive
to the number of independent snapshots considered (63). Therefore, results on
conformational entropies should be taken only as suggestive.
Solvent contributions to free energy were calculated using the molecular
mechanics-Poisson Boltzmann surface area (MM-PBSA) methodology (62,63);
for each relevant conﬁguration we saved 200 snapshots from the last 2 ns of
MD runs. Since DGsolv ¼ Gcomplexsolv  Gdrugsolv  GDNAsolv and the last two terms in
the right-hand side are the same for each conﬁguration of the complex,
DGsolv is directly proportional to G
complex
solv : Based on this proportionality,
only this latter term was evaluated for each relevant conﬁguration of the two
complexes. The electrostatic contribution to solvation was evaluated using
the Poisson-Boltzmann continuum method (66), as implemented in the
module pbsa (67) of AMBER 9. We set the values of internal and external
dielectric constants to 1 and 80, respectively, the grid twice as long as the
linear dimensions of the solute, and a grid spacing of 0.25 A˚. The dielectric
boundary is the molecular surface deﬁned by a 1.4 A˚ probe sphere and by
spheres centered on each atom with radii taken from the PARSE (68)
parameter set (H¼ 1.0, C¼ 1.7, N¼ 1.5, andO¼ 1.4 A˚, with a value of 2.0
A˚ for the phosphorus). The boundary dielectric constants were set as the
harmonic sum of solvent and solute Debye-Huckel values. Salt effects were
not included implicitly in the continuum model. The hydrophobic compo-
nent of solvation free energy is assumed proportional to the change of the
solvent accessible surface area (SASA), DGnp ¼ gDSASA1b where g ¼
0.00542 kcal/A˚2 and b¼ 0.92 kcal/mol (68). For comparison, we performed
MM-PBSA calculations also using a new approach available in the pbsa
FIGURE 2 (a) PMF associated to DSI sliding along the DNA minor groove. Standard deviation is reported in the inset. (b) Schematic view of the
conﬁguration corresponding to the free energy minimum. (c) Structures of three relevant conformations of the complex. The third structure (from the left) was
rotated ;40 about the helical axis to center the drug for visualization. Molecular surfaces of drug and DNA are depicted in transparent red and blue,
respectively.
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module of the AMBER 9 package (61,67,69). In this method the nonpolar
contribution is cast into two terms, a repulsive one (cavity), correlated to the
SASA, and an attractive one (dispersion), calculated through a surface-
integration approach (70).
RESULTS AND DISCUSSION
Here we ﬁrst provide a description of the PMF proﬁles
corresponding to the sliding of IMI and DSI inside the minor
groove of oligonucleotides d(GCCAACGTTG*GC)-d(GCC
AACGTTGGC) and d(GACTAATTGAC)-d(GTCAATTA*
GTC) (IMIDNA and DSIDNA) respectively, considering
d[C-N] as the reaction coordinate (see Systems and Meth-
ods). Note that the standard deviation is very small along the
entire sampling interval (0.2 kcal/mol, see insets in Figs.
1 and 2), which makes the values of the free energy extracted
from our simulations quantitatively reliable. We then analyze,
at the qualitative level, the enthalpic and entropic contribu-
tions to the PMF from the solute and the effects of the
solvent. We close this section by assessing the relevance of
end effects (12) on the energetics of the sliding process.
PMF proﬁles
The PMF of IMIDNA features four minima (I–IV, Fig. 1).
In I, the complex is in its reactive conﬁguration, i.e., carbon
C11@IMI faces N2@G10 (d[C-N] 3 A˚). This corresponds
to the average structure assumed by the complex during the
ﬁrst 10 ns of a 20 ns long MD simulation (12). From I, a
small barrier of 1.5 kcal/mol has to be overcome at transition
state I* to reach the absolute minimum II, where d[C-N] 
5.6 A˚. In II, C11@IMI sits slightly before the T9 plane
(along the direction 39/59), and IMI sits at the same
location as in the last 10 ns of a 20 ns long MD simulation
(12). Interestingly, the barrier from II to I (5.5 kcal/mol) is
much larger than that from I to II, consistently with Vargiu
et al. (12), which suggests that IMI is stable in II after its
departure from I. At larger d[C-N] distances, we ﬁnd III
(7.2 A˚) and IV (10.1 A˚), in which C11@IMI is located imme-
diately beyond T9 and in front of O2@T8, respectively.
The PMF landscape of DSIDNA is remarkably different
(Fig. 2). Indeed, sliding is hindered by a barrier of ;4 kcal/
mol which traps the drug in the reactive conﬁguration I
(corresponding to the absolute minimum in the PMF, along
the investigated path). This minimum is followed by three
other ones (higher in energy by ;4 kcal/mol) virtually
isoenergetic. In such minima, the reactive group of the drug
(in particular C13@DSI) is in front of G20 (II, a very shallow
minimum), T21 (III), and between T21 and C22 (IV).
The PMF of IMIDNA appears to be much rougher than
that of DSIDNA and, in particular, features two conﬁgu-
rations corresponding to a larger gain in binding free energy
than in the reactive conformation. Results obtained for the
two adducts are in line with those extracted from previous
MD simulations (11,12) and may partly explain the higher
selectivity of duocarmycins as compared to anthramycins
(17,33). For instance, in IMIDNA the reactive conﬁguration
should be markedly less populated with respect to II (and
competitive with III and IV). In fact, within Arrhenius’s
theory, and assuming the same prefactor at conﬁgurations I
and II, the former will be e(3/0.6)  150 times less likely. In
contrast, in DSIDNA there is a deﬁnite larger gain in the
binding free energy at the reactive conﬁguration, with an
almost ﬂat PMF landscape elsewhere.
Dissection of the PMFs
The PMF can be interpreted as the change in binding free
energy DGb upon drug sliding. To identify the relevant con-
tributions to this process, we can express DGb changes as a
sum of individual terms (5,30,71,72). Here we decompose
DGb in a term due to solute conformation and interactions
between the two moieties (solute terms) and a second one due
to the presence of water and counterions (solvent effects):
DGb ¼ DGsolute1DGsolv; (1)
where
DGsolute ¼ DHadapt1DHel1DHvdW  TDSvib  TDSr1t (2)
DGsolv ¼ DGsolv; p1DGsolv; np: (3)
In Eq. 2, DHadapt represents the enthalpic term due to DNA
and drug structural deformations upon binding, and DHel
and DHvdW are contributions from electrostatic and van der
Waals interactions, respectively. We approximately esti-
mated DHadapt and DHel using terms of the AMBER force
ﬁeld (25,26,37,38), whereas DHvdW was assumed to be
roughly proportional to the variation in the number of hy-
drophobic contacts (see Systems and Methods and Supple-
mentary Material Table S3). TDSvib and TDSr1t are the free
energy contributions due to vibrational and translational1
rotational entropy changes upon binding. The former was
evaluated through normal mode analysis (60), whereas TDSr1t
was assumed to be sequence independent (32). In Eq. 3,
DGsolv,p andDGsolv,np are respectively the polar (electrostatic)
and nonpolar (hydrophobic) contributions to solvation, eval-
uated here with the MM-PBSA method (see Systems and
Methods). We point out that although the PMFs are quan-
titatively reliable, their dissection into enthalpic, entropic,
and solvation terms was carried out using approximated and/
or strongly sampling-dependent methods. Thus, these con-
tributions have to be considered qualitatively, and are here
used to gain insights into the sources of drug selectivity. In
the following, all the values we discuss refer to the reactive
conﬁguration in each complex, which is indicated as I.
Solute terms
First, we report the analysis of enthalpic terms for IMIDNA,
summarized in Table 1 and in Fig. 3, a–c, for DHadapt, DHel,
and number of contacts, respectively. As shown in Vargiu
et al. (12), at I the DNA is distorted in the central C6G7 tract
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with respect to its structure in bulk solvent. The adaptation
energy further increases going from I to the maximum I*,
whereas drug/DNA interactions weaken. Both this and the
previous works indicate that the whole structure relaxes at II
(indeed, the conformation assumed by the oligonucleotide is
very close to that of canonical B-DNA in aqueous solu-
tion), and both electrostatic and van der Waals interactions
strengthen. Actually, such interactions are the strongest
along the investigated path, whereas the adaptation expense
is the lowest. In contrast, the (average) number of direct
H-bonds decreases. The subsequent increase in free energy
at III* is partially due to the steric clash between the drug
acrylamide tail and the amino group of G7. The latter hinders
the sliding of the drug, causing a rotation of its principal axis
with respect to the oligonucleotide and slightly exposing the
molecule to the solvent (see Supplementary Material SM_II).
Correspondingly, the number of contacts reaches a minimum
in III*, and the minor groove widens in the tract C6. . .T8
(average width 8 A˚ with respect to 4 A˚ at II). Once the
guanine amino group is overcome by the drug, a wide free
energy minimum is reached in the proximity of T8 (IV).
Here, the drug recovers some of the contacts with the DNA
backbone.
The (solute) enthalpic contributions fairly correlate with
the PMF (Fig. 3, a–c), although deviations are present, point-
ing to the role of solute entropic and/or solvation terms. This
is particularly evident at PMF transition states; for example,
the sum of the enthalpic terms indicates II* to be lower than
III*, whereas in the PMF III* is slightly lower than II* (Table
1). Nevertheless, we can conclude that for IMIDNA the
(solute) DH landscape has the same overall trend shown by
the PMF.
Concerning solute vibrational entropies, the calculated
values at minima of the PMF turn out to scarcely differ
(Supplementary Material Table S4), consistent with previous
results (12). Given the limitations of the methodology used
here (63), we take these values as an indication only that
solute entropy does not vary signiﬁcantly at different
conﬁgurations.
In DSIDNA, the free energy absolute minimum I, corre-
sponding to the reactive conﬁguration, shows the lowest
DHadapt (Fig. 3 e and Table 1) and the largest number of
hydrophobic contacts (Fig. 3 g and Table 1), whereas DHel is
very similar to the values in II and III (Fig. 3 f and Table 1).
The major source of stabilization in I is the extended pattern
of hydrophobic contacts formed between the drug and the
DNA, in agreement with experimental suggestions (17,18).
The drug is signiﬁcantly distorted when leaving the reactive
conﬁguration: the twist between the two drug moieties
increases from;20 at I to;110 at I*, causing a signiﬁcant
widening of the minor groove (see SM_III). Consequently,
the block A (Chart 1), along with the minor groove ﬂoor (see
also next section and Fig. 3 h), is more solvent exposed, the
electrostatic interactions weaken, and the number of drug/
DNA hydrophobic contacts decreases drastically. Addition-
ally, the H-bond which forms discontinuously at the reactive
conﬁguration is here deﬁnitively lost. At II*, both the DNA
and the drug are less distorted than in I*, and the number
of hydrophobic contacts is the same as in I. Surprisingly,
the adaptation cost is essentially the same as in I*. II is
characterized by a small gain in electrostatic and adaptation
energies as compared to II* and III*, along with the recovery
of one H-bond. However, it features fewer hydrophobic
contacts than II* and III*. Apart from the reactive conﬁg-
uration, III is the lowest enthalpic minimum; however, its free
energy value is almost identical to those at II and IV (Fig. 2 a).
In summary, the (solute) enthalpic analysis shows that sev-
eral points lack correspondence with the PMF, indicating
a key role of entropy and/or solvent effects for the sliding
process of DSI. Nevertheless, enthalpy contributions unam-
biguously pinpoint the conﬁguration I as the most stable one,
with DHadapt playing a more important role than in IMI
DNA (max DDHadapt ¼ 18 and 7 kcal/mol for DSI and IMI,
respectively).
TABLE 1 Selected values of solute DHadapt (column II), drug/DNA DHel (column III), number of hydrophobic contacts (column IV),
average number of H-bonds (column V), polar (column VI), and nonpolar (column VII) contributions to DGsolv
dC-N (A˚) DHadapt DHel No. contacts No. H-bonds DGsolv,p DGsolv,np
IMIDNA 3.2 (I) 0.0(22.7) 0.0(1.6) 15(4) 2.0(0.8) 0.0(34.2) 0.0(2.0)
3.9 (I*) 19.6(22.3) 13.3(1.3) 12(3) 0.9(0.6) 38.7(50.2) 2.1(2.4)
5.6 (II) 7.0(21.6) 2.4(1.1) 19(3) 1.2(0.6) 8.8(47.3) 4.6(1.8)
6.5 (II*) 3.8(21.6) 1.0(1.8) 13(3) 0.6(0.5) 17.5(35.4) 12.0(2.2)
7.2 (III) 4.9(22.2) 11.2(1.1) 11(3) 1.0(0.2) 111.4(36.7) 14.2(2.4)
8.2 (III*) 1.4(21.8) 12.2(1.3) 9(2) 0.5(0.3) 16.4(31.6) 14.8(1.7)
10.1 (IV) 1.5(22.4) 1.4(1.0) 15(3) 0.5(0.5) 1.5(53.2) 2.1(3.0)
DSIDNA 3.0 (I) 0.0(18.1) 0.0(1.9) 63(10) 0.5(0.3) 0.0(36.0) 0.0(2.0)
4.3 (I*) 118.3(18.2) 16.3(2.0) 47(9) 0.0(0.0) 60.2(45.6) 17.4(2.6)
6.0 (II*) 118.6(18.1) 13.6(1.7) 63(11) 0.0(0.0) 41.3(29.6) 10.3(2.8)
7.0 (II) 117.6(18.2) 12.2(5.2) 53(12) 0.8(0.4) 25.6(35.0) 11.3(2.4)
8.9 (III*) 119.9(18.5) 13.7(2.4) 56(11) 0.0(0.0) 34.5(40.0) 11.4(2.5)
10.3 (III) 115.7(18.1) 1.2(2.2) 58(10) 0.9(0.6) 44.4(41.4) 13.9(2.0)
11.9 (IV) 114.1(18.5) 15.3(1.5) 54(11) 0.0(0.0) 49.5(39.1) 12.9(2.0)
Energies are in kcal/mol and referred to the values at conﬁguration I. Standard deviations are reported in parentheses.
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FIGURE 3 Selected values of (a and
e) DHadapt; (b and f) DHelec; (c and g)
number of hydrophobic contacts; (d and
h) electrostatic (squares, dotted-dashed
line), hydrophobic (rhombus, dashed
line), and total (circles, solid line)
DGsolv along the reaction coordinate
d[C-N], compared to the PMF (dotted
line, and rescaled in (c, d, g, and h) to
allow for an easier comparison with
DGsolv proﬁles). Data on the left (a–d)
refer to IMIDNA, those on the right
(e–h) to DSIDNA. Solvation free en-
ergies were obtained using the method
of Luo and co-workers. For a compar-
ison with data obtained using PARSE
radii, see Supplementary Fig. S3.
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Finally, we evaluate TDSvib at the minima of the PMF. The
calculated values show a range of variation comparable to
that found for IMIDNA (Supplementary Material Table S4),
and we assume also in the case of DSI to neglect solute
entropic contributions to the sliding process.
Solvent effects
The analysis of DGsolute carried out above clearly points to
the role of solvent for the sliding of the two investigated
drugs, in particular for DSI. It is indeed well known that
solvent is crucial for nucleic acid structure and stability, and
consequently it is important for the binding of drugs to DNA.
The development of reliable implicit solvent models and fast
ﬁnite difference numerical procedures (67–70,73) has made
feasible the calculations of solvation free energy via MD
simulations. In particular, binding free energies of ligands to
DNA calculated with the MM-PBSA method agree fairly
well with experimental values (29,30,64).
We evaluate here both electrostatic (DGsolv,p) and hydro-
phobic (DGsolv,np) contributions to DGsolv, which can be
interpreted as the free energy cost for drug desolvation upon
binding, using either the ‘‘standard’’ setup (63,68) or the
alternative approach available in AMBER (61,67,69,70) (see
Systems and Methods). We stress that binding is here always
associated to an unfavorable—positive—change in solvation
free energy. DGsolv proﬁles evaluated with the two method-
ologies are very similar, although the second approach
(61,67,69,70) highlights the sequence dependence of non-
polar contributions (Figs. 3, d and h, and Supplementary
Material Fig. S3). The changes in DGsolv turned out to be
very large compared to the PMF and characterized by large
standard deviations (Fig. 3, d and h), as reported by other
authors (30,64). For these reasons, calculated DGsolv are only
used for qualitative purposes. Nevertheless, some interesting
differences between IMI and DSI are observed: i), The cost
in desolvation upon formation of the complex DGsolv is the
highest at the absolute PMF minimum in DSIDNA (Fig.
3 h), in agreement with the better ﬁt of the drug into the
minor groove at I. Already at I*, where drug distortion re-
sults in its enhanced solvation, DGsolv suddenly decreases
and reaches a rough plateau for the other conﬁgurations. This
behavior mirrors the PMF landscape, where the minimum
corresponding to the reactive conﬁguration is the lowest. ii),
By contrast, DGsolv does not show any clear correlation with
the PMF in IMIDNA. In particular, the deepest minimum in
the PMF is not associated with the highest value of DGsolv
(highest solvation cost). We also notice that density plots for
water (SM_II and SM_III) exhibit qualitatively the same
trend of the proﬁle of DGsolv. In particular, in both IMIDNA
and DSIDNA I* features, there is more water inside the
groove with respect to I, and in IMIDNA III has the largest
desolvation cost, consistent with its very poor hydration (see
SM_II). Interestingly, the number of hydrophobic contacts in
III is lower than that of II, indicating that this number does
not necessarily increase with a lower degree of hydration.
This might be due, at least in part, to the ‘‘bridging’’ of the
two DNA strands by the drug, which prevents water to
access the groove around the binding region (see SM_II).
Within the limitations of our analysis, we conclude that
solvent effects may play a key role in DSIDNA, consistent
with the ﬁnding that DGsolute does not correlate with the
PMF. Instead, no clear correlation exists between the PMF
and DGsolv in IMIDNA, which is also consistent with the
rough correlation found between DGsolute and the PMF.
Evaluation of end effects
In our PMF calculations, we selected as starting conforma-
tion the alkylation sites of IMI and DSI, as those are the only
ones deﬁnitely visited by the drugs. These sites correspond to
the G10 and A19 in IMIDNA and DSIDNA, respectively.
(Indicating such nucleobases with the asterisk the sequence
are d(GCCAACGTTG*GC)-d(GCCAACGTTGGC) and
d(GACTAATTGAC)-d(GTCAATTA*GTC) for IMIDNA
and DSIDNA, respectively.) When building up the sliding
windows as described in Systems and Methods, DSI turned
out to slide toward the 39 end of the strand containing A19,
whereas in IMIDNA the drug moves toward the oligonu-
cleotide center. As a result, the regions explored by the two
drugs are slightly different (although it should be noticed that
they are comparable, as can be seen from Figs. 1 and 2), and
diverse inﬂuence of ‘‘end effects’’ (12) might hamper a
thorough comparison between the calculated PMFs.
In this respect, we have already shown that end effects
play only a minor role on the dynamics of IMIDNA (12).
Here we perform MD calculations to assess the possible
inﬂuence of such effects on the interaction between DSI
and DNA. Speciﬁcally, we compare the last 2 ns from MD
simulations of two identical tracts DSId[GACT]2 either
embedded in the 11-mer DSIDNA (DSId[G1A2C3T4]2) or
in the 14-mer DSIDNAc (DSId[G4A5C6T7]2; see Systems
and Methods).
The structure, the conformational ﬂexibility, the hydration
of DSId[G1A2C3T4]2, and DSId[G4A5C6T7]2 turned out
to be rather similar, along with the interactions between DSI
and the tracts d[GACT]2. In fact
i. The structures ofDSId[G1A2C3T4]2 andDSId[G4A5C6T7]2
are almost superimposable (Supplementary Material
Fig. S4), and the calculated RMSD is consistently 0.6
A˚. Furthermore, the widths of minor grooves at the
binding region are comparable, with or without the
presence of three additional nucleobases (Supplemen-
tary Material Table S5 and Fig. S4), and, independent
from the length of the duplex, DSI does not ﬁt perfectly
into the minor groove. In consequence of these struc-
tural similarities in both DSIDNA and DSIDNAc, the
methoxyl-carbonyl ester (Chart 1) of the drug is fully
solvated.
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ii. The number of hydrophobic contacts and H-bonds be-
tween DSI and d[GACT]2 is almost the same (Supple-
mentary Material Table S6).
iii. The DSI-Owat and DSI-Hwat radial distribution func-
tions, which provide information on the solvation of the
drug, are rather similar too (Supplementary Material
Fig. S5). Consistently, the ﬁrst and second solvation
shells around the drug contain virtually the same
number of waters (Supplementary Material Table S5).
This is not unexpected due to the excellent superimpo-
sition between the two tracts (Supplementary Material
Fig. S4) and the comparable hydration of the DSI
methoxyl-carbonyl ester. In particular, O14DSI (Chart
1), which in DSIDNA is the drug acceptor (pointing to
the minor groove) closest to the duplex end, forms in
both cases one H-bond with similar lifetimes (Supple-
mentary Material Table S8). Interestingly, the tracts
d[G1A2]2 and d[G4A5]2 also do not show relevant
differences in their H-bond patterns (Supplementary
Material Table S8). Finally, the density plots of waters
extracted from MD simulations are rather similar too
(Supplementary Material Fig. S6).
iv. The values of the root mean-square ﬂuctuations do not
differ signiﬁcantly, apart from the terminal sugar moie-
ties, which are obviously more ﬂexible in DSIDNA
(Supplementary Material Fig. S7).
v. The electrostatic energy between DSI and tracts d[GACT]2
is exactly the same in both systems (Supplementary
Material Table S6).
Summarizing, end effects seem to play a minor role on the
interactions between the two drugs and the DNA duplexes,
even though they do slightly inﬂuence the structure of water
within the minor groove. In conclusion, these ﬁndings con-
ﬁrm that steric hindrance and optimal interactions with the
groove have a prominent role in determining the preferred
binding sequence of duocarmycin.
CONCLUSION
The PMFs associated with the sliding of IMI and DSI along
the DNA minor groove differ remarkably (Figs. 1 and 2).
The reactive conﬁguration is the most favorable for DSI
DNA, whereas in IMIDNA signiﬁcant activation energy is
required to reach the reactive site moving from the absolute
PMF minimum (corresponding to a nonreactive conﬁgura-
tion). Results are consistent with previous MD simulations of
IMIDNA (12), showing that the reactive conﬁguration be-
comes unstable after a few ns and with those of DSIDNA
(11), in which the drug is stable in the reactive conﬁguration
for the whole dynamics. Moreover, our ﬁndings indicate that
the higher speciﬁcity of DSI, compared to IMI, correlates
with a higher cost for moving the drug from the preferred
site, at least for the sequences considered here. End effects
turn out not to play a relevant role for the binding.
For both complexes, conﬁgurations associated with the
absolute minima of the PMF are those with the smallest ad-
aptation cost and the better packing (Table 1). This is con-
sistent with the usual assumption of negligible DHadapt upon
drug binding to the preferred sequence in the minor groove
(5,30,32). Apart from this common feature, the various
contributions to the PMF have different relative weights for
the two adducts. In IMIDNA the changes in enthalpic terms
correlate fairly well with the PMF, particularly at the four
minima, whereas the DGsolv landscape is apparently unrelated
to the free energy proﬁle. In DSIDNA we found instead
a rough anticorrelation between DGsolv and the PMF proﬁle,
whereas enthalpy contributions do not have an overall corre-
spondence with the free energy proﬁle, except for the coin-
cidence of absolute minima.
In summary, our calculations suggest that for alkylating
agents, shape complementarity and packing are also signif-
icant factors in determining the preferred site of noncovalent
binding (30,71,74,75). In addition, they give insights into the
way differences in chemical structure, size, and ﬂexibility
may inﬂuence solvation and molecular recognition along the
minor groove. In this respect DSI, due to its larger size rel-
ative to IMI, covers more DNA bps and needs to rotate
around the linkage between groups A and B (Chart 1) to ﬁt in
the preferred sequence. The cost of such a rotation (which
was supposed to be a key factor for reactivity) depends
on the ﬂexibility and structure of the target DNA sequence.
Furthermore, the lack of optimal docking results in a larger
drug exposure to the solvent, a feature that we do not ﬁnd
for IMIDNA, in which drug desolvation cost is uncorre-
lated to sequence selectivity. This is consistent with the fact
that IMI already has the right conformation to ﬁt snugly into
the minor groove at different sequences (indeed the reac-
tive conﬁguration does not correspond to a minimum in
DHadapt) and features a lower sequence selectivity compared
to DSI.
Finally, although speculative, different molecular recog-
nition mechanisms can be proposed for the two drugs inves-
tigated here. DSI might ﬁrst bind to DNA at those sequences
characterized by the lowest desolvation cost (the nonpre-
ferred ones) and then easily slide toward the preferred site,
corresponding to a funnel in the PMF. In this scenario, sol-
vent effects could be critical for the molecular recognition of
DNA by duocarmycins. In contrast, recognition of DNA by
anthramycin appears to be more complicated, since, accord-
ing to our results, no preferred route exists. Moreover, the re-
active site can be reached only upon crossing a signiﬁcant
free energy barrier.
Clearly, calculations of free energy barriers to form non-
covalent complexes at different sequences, also with drugs
other than those considered here, are needed to achieve a gen-
eral picture of themolecular recognition.However, our results
help to rationalize the higher selectivity of duocarmycins
compared to anthramycins and point out clearly the possibil-
ity of multiple patterns for molecular recognition.
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